- JP-listed companies
- Income statement
(E27038) Income statement
Market cap
P/E ratio
UMN Pharma develops innovative vaccines for infectious diseases like norovirus and rotavirus while providing contract manufacturing services for biopharmaceuticals.
| 2009/12 | 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | |
| Revenue | - | 2,000 | 1,000 | 108 | 93 | 1,109 | 190 | 53 | 104 | 104 |
| Cost of revenue | - | - | - | 17 | 27 | 174 | 136 | 51 | 3 | 2 |
| Gross profit | - | - | - | 91 | 66 | 935 | 54 | 1 | 101 | 102 |
| Gross margin (%) | - | - | - | |||||||
| Operating expenses | - | - | - | 1,482 | 3,368 | 3,796 | 764 | 553 | 599 | 709 |
| Operating income | - | - | - | -1,391 | -3,301 | -2,861 | -710 | -552 | -498 | -607 |
| Income before tax | -736 | 423 | -589 | -1,326 | -3,179 | -2,820 | -614 | -481 | -158 | -610 |
| Provision for income taxes | - | - | - | 3 | 28 | 2 | 3 | -2 | 1 | 2 |
| Net income | -738 | 420 | -230 | -1,329 | -3,207 | -2,822 | -617 | -8,344 | -159 | -729 |
| Earnings per share | -197.06 | 103.75 | -51.41 | -279.87 | -424.14 | -322.29 | -64.48 | -804.39 | -12.96 | -55.12 |